Találati lista | Tudóstér

001-es BibID:	BIBFORM073712
Első szerző:	Csaba Zsolt
Cím:	Szövettan / Csaba Zsolt, Csáki Ágnes, Fejér Zsolt, Gerendai Ida, Kausz Mária, Kittner Zsuzsa, Kocsis Katalin, Köves Katalin, L. Kiss Anna, Lantos Tibor, Magyar Attila, Molnár Judit, Nagy György, Nemeskéri Ágnes, Németh Anna, Oláh Imre, Röhlich Pál, Szeiffert Gábor, Szél Ágoston, Tóth Béla, Vígh Béla
Dátum:	2014
Megjelenés:	Budapest : Semmelweis Kiadó, 2014
Terjedelem:	252 p.
ISBN:	9789633313220
Tárgyszavak:	Orvostudományok Klinikai orvostudományok tankönyv
További szerzők:	Csáki Ágnes Fejér Zsolt Gerendai Ida Kausz Mária Kittner Zsuzsa Kocsis Katalin Köves Katalin Kiss Anna L. Lantos Tibor Magyar Attila Molnár Judit Nagy György Nemeskéri Ágnes Németh Anna Oláh Imre Röhlich Pál Szeiffert Gábor Szél Ágoston Tóth E. Béla (1960-) (orvos) Vígh Béla
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM073593
Első szerző:	Gadó Klára
Cím:	Prolactin influences proliferation and apoptosis of a human IgE secreting myeloma cell line, U266 / Klara Gadó, Éva Pállinger, Péter Kovács, Edit Takács, István Szilvási, Béla E. Tóth, György Nagy, Gyula Domján, András Falus
Dátum:	2002
ISSN:	0165-2478
Megjegyzések:	In certain types of solid tumours and lymphomas prolactin (PRL) potentiates tumour cell proliferation and exerts anti-apoptotic effect. Tumour cells themselves can produce PRL and express PRL-receptors. Hyperprolactinemia is associated with different tumours, also. Multiple myeloma (MM) is a haematological malignancy caused by the clonal expansion of terminally differentiated plasma cells in the bone marrow. Recently, we demonstrated PRL immunostaining in bone marrow cells of MM patients and an elevated level of serum PRL of MM patients with advanced disease. In the present study, we tested the effect of PRL on a U266 human myeloma cell line and demonstrated constitutive and melphalan-stimulated intracytoplasmic PRL in U266 cells. Exogeneous PRL inhibited the proliferation and immunoglobulin (Ig) production of U266 myeloma cells. Concerning etoposide-induced apoptosis, PRL had a double-faceted effect depending on the applied dose: high, pharmacological doses (corresponding to hyperprolactinemia), inhibited apoptosis, whereas near physiological doses exerted a pro-apoptotic effect. These data indicate a definite effect of PRL on a human myeloma cell line. We demonstrated a direct inhibition of PRL on tumour cell growth, while its reciprocal effect on apoptosis refers to an important regulatory role of PRL.
Tárgyszavak:	Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Immunology Letters 82 : 3 (2002), p. 191-196. -
További szerzők:	Pállinger Éva Kovács Péter (Budapest) Takács Edit Szilvási István Tóth E. Béla (1960-) (orvos) Nagy György Domján Gyula Falus András
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM073597
Első szerző:	Gadó Klára
Cím:	Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients / Klára Gadó, György Nagy, Ágnes Hasitz, Béla E. Tóth, Éva Rimanóczi, Gyula Domján
Dátum:	2001
ISSN:	1021-7401
Megjegyzések:	The role of prolactin (PRL) in the physiological regulation of the immune system and in hematopoiesis is well known. There is also evidence of the significance of PRL in several pathological conditions such as autoimmune diseases and some malignancies, e.g. colon and breast carcinomas and also B cell malignancies. Multiple myeloma is known as a B cell malignancy. It is the result of malignant transformation of a single clone of neoplastic plasma cells that synthesize abnormal amounts of monoclonal immunoglobulins or immunoglobulin fragments. In our present studies, the possible expression of PRL in bone marrow cells obtained from diagnosed multiple myeloma (17 cases) or nonmyeloma (5 cases) patients was examined by the method of immunocytochemistry. Samples obtained from those multiple myeloma patients (13 cases) who had not received chemotherapy for 6 months prior to these studies showed a positive immunocytochemical reaction for PRL. Bone marrow smears of patients diagnosed with multiple myeloma who had received chemotherapy within 6 months of the study and also the smears of patients without diagnosed multiple myeloma failed to show a positive immune reaction for PRL. In the case of a patient who was examined prior to and also after a period of 3 months of chemotherapy, the PRL-immunopositive bone marrow cells had disappeared due to the treatment. According to the light microscopic analysis of the cell morphology, PRL-immunopositive cells in the bone marrow were mainly, but not exclusively, plasma cells. There was no correlation between the positive PRL staining of cells and the type of monoclonal immunoglobulin or the ratio of plasma cells detected in the bone marrow. Taken together, our results indicate a possible role of PRL in multiple myeloma. Further experiments are necessary to identify the prognostic value of PRL in multiple myeloma.
Tárgyszavak:	Orvostudományok Gyógyszerészeti tudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Neuroimmunomodulation 9 : 2 (2001), p. 95-102. -
További szerzők:	Nagy György Hasitz Ágnes Tóth E. Béla (1960-) (orvos) Rimanóczi Éva Domján Gyula
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: